DSM Capital Partners LLC Buys 14,225 Shares of Stryker Corporation $SYK

DSM Capital Partners LLC boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 315.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,731 shares of the medical technology company’s stock after acquiring an additional 14,225 shares during the quarter. Stryker accounts for 0.1% of DSM Capital Partners LLC’s portfolio, making the stock its 28th largest position. DSM Capital Partners LLC’s holdings in Stryker were worth $6,924,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Cerity Partners LLC boosted its stake in shares of Stryker by 1.1% in the 3rd quarter. Cerity Partners LLC now owns 317,999 shares of the medical technology company’s stock valued at $117,554,000 after purchasing an additional 3,419 shares in the last quarter. SeaBridge Investment Advisors LLC lifted its holdings in Stryker by 4.8% during the 3rd quarter. SeaBridge Investment Advisors LLC now owns 7,810 shares of the medical technology company’s stock valued at $2,887,000 after purchasing an additional 356 shares during the last quarter. Kathmere Capital Management LLC boosted its position in Stryker by 4.3% in the third quarter. Kathmere Capital Management LLC now owns 897 shares of the medical technology company’s stock valued at $332,000 after buying an additional 37 shares in the last quarter. Gladstone Institutional Advisory LLC grew its stake in Stryker by 1.6% during the third quarter. Gladstone Institutional Advisory LLC now owns 2,410 shares of the medical technology company’s stock worth $891,000 after buying an additional 38 shares during the last quarter. Finally, Milestone Asset Management Group LLC grew its stake in Stryker by 26.6% during the third quarter. Milestone Asset Management Group LLC now owns 753 shares of the medical technology company’s stock worth $278,000 after buying an additional 158 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Trading Up 5.1%

SYK stock opened at $366.46 on Wednesday. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a market cap of $140.14 billion, a P/E ratio of 48.16, a PEG ratio of 2.23 and a beta of 0.89. The business has a fifty day moving average of $359.75 and a 200-day moving average of $375.35.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Friday, October 31st. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The company’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the company earned $2.87 earnings per share. As a group, equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. This is a positive change from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s payout ratio is presently 46.25%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 522,118 shares of company stock worth $185,381,932 over the last ninety days. Company insiders own 5.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on SYK. Raymond James Financial raised Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price on the stock in a report on Tuesday. UBS Group set a $408.00 price objective on Stryker in a research report on Monday, October 13th. Rothschild & Co Redburn started coverage on Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $448.00 target price on shares of Stryker in a research note on Friday, November 14th. Finally, Evercore ISI set a $390.00 price target on Stryker in a report on Monday. Fourteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $430.40.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.